Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Therapeutic Endpoint in Pediatric IBD Conditions

NCT: NCT06065228 · RECRUITING

NCT IDNCT06065228
StatusRECRUITING
Start Date2023-11-27
Completion2027-12

Brief Summary

The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. Data from the device provides an assessment of disease activity and a more precise approach to treatment.

Frequently Asked Questions

What is Therapeutic Endpoint in Pediatric IBD Conditions?

Therapeutic Endpoint in Pediatric IBD Conditions is a clinical trial registered under NCT06065228. Current status: RECRUITING.

What is the status of NCT06065228?

The current status of NCT06065228 (Therapeutic Endpoint in Pediatric IBD Conditions) is: RECRUITING.

When did Therapeutic Endpoint in Pediatric IBD Conditions start?

Therapeutic Endpoint in Pediatric IBD Conditions started on 2023-11-27.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.